Abstract

Small-cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. To identify accurate predictive biomarkers and effective therapeutic modalities, we focus on a long noncoding RNA, Hox transcript antisense intergenic RNA (HOTAIR), and investigated its expression, cellular functions, and clinical relevance in SCLC. In this study, HOTAIR expression was assessed in 35 surgical SCLC samples and 10 SCLC cell lines. The efficacy of knockdown of HOTAIR by siRNA transfection was evaluated in SBC-3 cells in vitro, and the gene expression was analyzed using microarray. HOTAIR was expressed highly in pure, rather than combined, SCLC (P = 0.012), that the subgroup with high expression had significantly more pure SCLC (P = 0.04), more lymphatic invasion (P = 0.03) and more relapse (P = 0.04) than the low-expression subgroup. The knockdown of HOTAIR in SBC-3 cells led to decreased proliferation activity and decreased invasiveness in vitro. Gene expression analysis indicated that depletion of HOTAIR resulted in upregulation of cell adhesion-related genes such as ASTN1, PCDHA1, and mucin production-related genes such as MUC5AC, and downregulation of genes involved in neuronal growth and signal transduction including NTM and PTK2B. Our results suggest that HOTAIR has an oncogenic role in SCLC and could be a prognostic biomarker and therapeutic target.

Highlights

  • Lung cancer is a leading cause of cancer death worldwide [1]

  • We first demonstrated that Hox transcript antisense intergenic RNA (HOTAIR) was expressed in pure Small-cell lung cancer (SCLC) and higher expression was significantly related to lymphatic invasion and relapse

  • In vitro experiments demonstrated that half of SCLC cell lines expressed HOTAIR at higher levels than normal cells and that, using SBC-3 cells, knockdown of HOTAIR decreased proliferative activity and cellular invasiveness with altered expression of cell adhesion-related genes

Read more

Summary

Introduction

Lung cancer is a leading cause of cancer death worldwide [1]. Small-cell lung cancer (SCLC) is an aggressive subtype, characterized by a neuroendocrine nature, which represents ~15% of all newly diagnosed lung cancers [2]. SCLC patients have a poor prognosis compared with non–small-cell lung cancers (NSCLCs) due to more rapid growth and more frequent recurrence. The survival of NSCLC patients has been significantly improved by targeted chemotherapy, there are currently no targeted drugs effective against SCLC. To identify accurate predictive biomarkers and to develop effective therapeutic modalities, elucidation a 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Cancer Medicine published by John Wiley & Sons Ltd

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.